This website is intended for healthcare professionals only

Trending Topic

16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]

36/Optimising pacemaker therapy using multi-point pacing (the OPT-MPP Study)

JE Lowry – University of Leeds, Leeds; S Straw – University of Leeds, Leeds; CA Cole – University of Leeds, Leeds; MF Paton – University of Leeds, Leeds; MT Kearney – University of Leeds, Leeds; KK Witte – University of Leeds, Leeds; J Gierula (Presenting Author) – University of Leeds, Leeds
2 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr36
Select a Section…
1

Article

Background: Heart failure with reduced ejection fraction (HFrEF) is characterised by an attenuation of the positive relationship between heart rate and left ventricular (LV) contractility, known as the force-frequency relationship (FFR). Optimal therapy for around 1/3 of people with HFrEF includes a resynchronisation (CRT) cardiac implantable electronic device (CIED). We have previously demonstrated that programming the CIED to maintain the heart rate within a range for optimal cardiac contractility is associated with improved exercise capacity. Multi-point pacing (MPP) has been proposed as a method of improving CRT. Whilst MPP allows the opportunity to pace the heart over a wider area, there is no consistent improvement in terms of cardiac structure and function.

Purpose: To explore the effect of MPP on the FFR, exercise capacity and cardiac function.

Methods: A double-blind, randomised, crossover study explored the acute effects of MPP on the FFR, left ventricular function and acute exercise capacity. In random order, participants underwent an FFR assessment, and a treadmill walk test, once with MPP activated and once with standard CRT settings. The CIED was programmed back to the pre-test standard CRT settings after each treadmill test.

Results: A total of 23 people were recruited. We found no differences between phases in resting LV ejection fraction. There was an acute improvement in peak cardiac contractility of borderline statistical significance (2.37 ± 1.3 vs 2.12 ± 1.08; p=0.05), and a reduction in LV end systolic volume index ((65.9 ± 30.1 mL vs 72.7 ± 34.5 mL), mean difference between the groups of 11.5 mL (95% CI 1.8–11.8; p=0.01)) and LV end diastolic volume index (95.3 ± 38.1 mL vs 102 ± 40.8 mL; mean difference between the groups 6.7 mL [95% CL 0.26–13.1; p=0.04]). These acute improvements in cardiac function and volume did not lead to an improvement in treadmill walk time in the entire cohort.

Conclusion: MPP acutely improves peak cardiac contractility and induces reverse remodelling. However, this did not lead to an improvement in treadmill walk time. 

2

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup